Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Refractory CIDP
NCT05877040Phase 2Unknown
- Sponsor
- Humanitas Research Hospital
- Start
- Jun 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Humanitas Research Hospital. Status: unknown.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT05877040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877040.